Stage I HR-Positive Invasive Ductal Carcinoma: Amelia's Patient Story

What happened, in summary

Amelia was 40 when Stage I invasive ductal carcinoma was diagnosed. Her cancer was ER-positive, PR-positive, and HER2-negative. She first had an outpatient lumpectomy, but soon learned more surgery would be needed. Because she had a history of breast growths and wanted to lower future worry, she chose a bilateral mastectomy even before meeting with oncology. Genetic counseling showed she did not have a BRCA mutation. During the mastectomy, surgeons also removed lymph nodes from both sides and placed tissue expanders for reconstruction. After surgery, an Oncotype DX test came back at 22. The decision about chemotherapy was emotionally difficult because the cancer was small and the benefit was not guaranteed, but Amelia wanted to do everything she reasonably could to reduce recurrence risk. Her oncologist recommended TC chemotherapy: Taxotere and cyclophosphamide. She started within 3 months of diagnosis, lost her hair, and dealt with cumulative fatigue and appetite changes, but the chemotherapy was manageable. Her plastic surgeon filled the expanders between infusions, and about 1 month after chemotherapy she had exchange surgery to implants. Later reconstruction included nipple work and tattooing. As of June 2026, Amelia described herself as technically having no evidence of disease after surgery, while continuing tamoxifen as ongoing care.